NuCana (NASDAQ:NCNA) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.

NCNA has been the topic of a number of other reports. Zacks Investment Research upgraded shares of NuCana from a sell rating to a hold rating in a research note on Tuesday, July 23rd. William Blair reiterated an outperform rating on shares of NuCana in a research note on Thursday, May 16th. Finally, BidaskClub upgraded shares of NuCana from a strong sell rating to a sell rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. NuCana presently has a consensus rating of Buy and an average price target of $25.50.

Shares of NCNA stock traded down $0.13 on Thursday, hitting $8.65. The stock had a trading volume of 13,585 shares, compared to its average volume of 13,289. The stock has a market capitalization of $277.47 million, a price-to-earnings ratio of -15.18 and a beta of 3.27. The business has a 50 day simple moving average of $10.02. NuCana has a 52-week low of $7.53 and a 52-week high of $30.10.

NuCana (NASDAQ:NCNA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). On average, analysts predict that NuCana will post -1.14 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace North America L.P. boosted its stake in NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after acquiring an additional 51,607 shares during the last quarter. Rothschild Investment Corp IL bought a new position in NuCana during the 1st quarter valued at $211,000. Aperio Group LLC bought a new position in shares of NuCana in the 2nd quarter worth about $39,000. Asymmetry Capital Management L.P. lifted its position in shares of NuCana by 5.4% in the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after buying an additional 2,346 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of NuCana by 5.6% in the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock worth $1,323,000 after buying an additional 4,160 shares during the last quarter. Hedge funds and other institutional investors own 38.08% of the company’s stock.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Further Reading: Percentage Decliners

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.